# US 2024/0199718 A1 · GLP-1 Analogues

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199718 A1
- Document ID: US20240199718A1
- Status: Published application
- Kind: A1
- Application number: 18/515,712
- Filed: 2023-11-21
- Published: 2024-06-20
- Earliest claimed: 2018-04-05
- Assignees: Sun Pharmaceutical Industries Limited
- Applicants: Sun Pharmaceutical Industries Limited
- Inventors: Rajamannar Thennati; Nishith Chaturvedi; Vinod Sampatrao Burade; Pradeep Dinesh Shahi; Muthukumaran Natarajan; Ravishankara Madavati Nagaraja; Rishit Mansukhlal Zalawadia; Vipulkumar Shankarbhai Patel; Kunal Pandya; Brijeshkumar Patel; Dhiren Rameshchandra Joshi; Krunal Harishbhai Soni; Abhishek Tiwari
- Web page: https://patentgrep.com/patent/US20240199718A1

## CPC

- C07K 14/605: Glucagons
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.

## Claims

### Claim 1

A polypeptide comprising the amino acid sequence:
H-X2-X3-X4-G-T-F-T-S-D-V-S-S-Y-L-X16-G-Q-A-A-X21-E-F-X24-A-W-L-V-R-G-R-G-X33-X34
wherein X2 is Ser, Ser(OMe), D-Ser, D-Ser(OMe), Ala or Aib,;
X3 is absent or Gln;
X4 is Glu;
X16 is Glu;
X24 is lle;
X33 is Leu, -D-Leu, D-lle or lle;
X34 is absent and X21 is Lys wherein the side chain amino (ε amino) group of Lys is acylated with a moiety:
{-Q-T-U-W-Y-Z
wherein Q and T are absent;
U is absent or —C(O)—CH2—O—(CH2)2-O-(CH2)2—NH—} wherein } is point of attachment with group W;
W is absent or selected from a group consisting of —C(O)—CH2—O—(CH2)2—O—(CH2)2—NH—], —C(O)—NH—(CH2)3−4—NH—], —C(O)—C(CH3)2—NH—] and
wherein ] is point of attachment with group Y;
Y is—C(O)—(CH2)2—CH(COOH)NH— and — is point of attachment with the group Z;
Z is —C(O)—(CH2)n—COOH or —C(O)—(CH2)n—CH3 wherein n is an integer from 14 to 20.

### Claim at position 2

2-10. (canceled)

### Claim 11

A compound of formula (I):
or a pharmaceutically acceptable salt thereof, wherein
n is an integer from 14-20;
R1 is CO2H, CH3 or CO2R5 wherein R5 is C1C4 alkyl;
R represents —OR2, an amino acid or a Glucagon-like Peptide-1 (GLP-1) agonist peptide or a salt thereof, wherein R2 is hydrogen, a carboxylic acid activating group or an insoluble polymer support; and
R3 represents H or lower alkyl.

### Claim 12 (depends on 11)

A compound according to claim 11, wherein R represents —OH, an insoluble polymer support, or a Glucagon-like Peptide-1 (GLP-1) agonist peptide.

### Claim 13 (depends on 11)

A compound according to claim 11, wherein n is 16.

### Claim 14 (depends on 11)

A compound according to claim 11, wherein R1 is CO2H or CO2R5.

### Claim 15 (depends on 11)

A compound according to claim 11, wherein R3 represents H or t-butyl.

### Claim 16 (depends on 11)

A compound according to claim 11, wherein R3 represents H, n is 16 and R1 is CO2H.

### Claim 17 (depends on 11)

A compound according to claim 11, wherein R is a peptide and is attached to the adjacent carbonyl via the ε amino of a lysine residue in the peptide.

### Claim 18 (depends on 16)

A compound according to claim 16, wherein R is a peptide attached to the adjacent carbonyl via the ε-amino of a lysine residue in the peptide.

### Claim 19 (depends on 11)

A compound according to claim 11, wherein R is a peptide and the peptide has the amino acid sequence:
H-X2-X3-X4-G-T-F-T-S-D-V-S-S-Y-L-X16-G-Q-A-A-X21-E-F-X24-A-W-L-V-R-G-R-G-X33-X34
(SEQ ID NO: 15) wherein
X2 is Ser, Ser(OMe), Aib, Ala, Gly, Val, Leu, lle, (1-amino C3-8 cycloalkyl) carboxylic acid, Trp or Thr;
X3 is absent or Gln;
X4 is Gln or Glu;
X16 is Glu or Asp;
X21 is Lys;
X24 is lle or Val or Leu;
X33 Leu, lle, Tyr or absent; and
X34 is Ser, Lys, Ala or absent.

### Claim 20 (depends on 18)

A compound according to claim 18, wherein R3 represents H and R represents a peptide having the amino acid sequence:
H-X2-X3-X4-G-T-F-T-S-D-V-S-S-Y-L-X16-G-Q-A-A-X21-E-F-X24-A-W-L-V-R-G-R-G-X33-X34
(SEQ ID NO: 15) wherein
X2 is Ser, Ser(OMe), Aib, Ala, Gly, Val, Leu, lle, (1-amino C3-8 cycloalkyl) carboxylic acid, Trp or Thr;
X3 is absent or Gln;
X4 is Gln or Glu;
X16 is Glu or Asp;
X21 is Lys;
X24 is lle or Val or Leu;
X33 Leu, lle, Tyr or absent; and
X34 is Ser, Lys, Ala or absent.

### Claim 21 (depends on 19)

A compound according to claim 19, wherein the peptide is attached to the adjacent carbonyl via the ε amino of a lysine residue in the peptide.

### Claim 22 (depends on 20)

A compound according to claim 20, wherein the peptide is attached to the adjacent carbonyl via the ε amino of a lysine residue in the peptide.

### Claim 23 (depends on 11)

A compound according to claim 11, wherein R represents —OR2 where R2 represents a carboxylic acid activating group or an insoluble polymer support.

### Claim 24 (depends on 23)

A compound according to claim 23, wherein R2 is an insoluble polymer support derived from an acid labile resin.

### Claim 25 (depends on 23)

A compound according to claim 23, wherein R2 is a insoluble polymer support derived from 2-chlorotrityl chloride.

### Claim 26 (depends on 11)

A compound according to claim 11, wherein R represents a lysine residue and is attached to the adjacent carbonyl via the ε amino of the lysine.

### Claim 27 (depends on 16)

A compound according to claim 16, wherein R1 is CO2H or CO2R5; and R3 represents H or lower alkyl.

### Claim 28 (depends on 17)

A pharmaceutical composition comprising a compound or salt thereof according to claim 17, together with one or more pharmaceutically acceptable excipients.

### Claim 29 (depends on 17)

A method of treating diabetes comprising administering to a patient in need thereof a compound or salt thereof according to claim 17.

### Claim 30 (depends on 29)

The method according to claim 29, wherein the diabetes is type 2 diabetes mellitus.

### Claim 31 (depends on 30)

The method according to claim 30, wherein the compound is administered simultaneously, separately, or sequentially in combination with an effective amount of one or more agents selected from metformin, thiazolidinediones, sulfonylureas, dipeptidyl peptidase 4 inhibitors, and sodium glucose co-transporters.

### Claim 32 (depends on 28)

A method of treating diabetes comprising administering to a patient in need thereof the pharmaceutical composition according to claim 28.

### Claim 33

A process for preparing a compound of formula (I):
or a pharmaceutically acceptable salt thereof, wherein
n is an integer from 14-20;
R1 is CO2H, CH3 or CO2R5 wherein R5 is C1-C4 alkyl;
R represents an amino acid or a Glucagon-like Peptide-1 (GLP-1) agonist peptide; and
R3 represents H or lower alkyl,
the process comprising reacting an amino acid or the Glucagon-like Peptide-1 (GLP-1) agonist peptide with a compound of formula (I-A)
wherein
n is an integer from 14-20;
R1 is CO2H, CH3 or CO2R5 wherein R5 is C1-C4 alkyl;
R3 represents H or lower alkyl, and
R2 represents H or a carboxylic acid activating group.

### Claim 34 (depends on 32)

A process for according to claim 32, wherein the amino acid is lysine and the compound of formula (I-A) reacts with the ε amino of the lysine.

### Claim 35 (depends on 32)

A process for according to claim 32, wherein the compound of formula (I-A) reacts with the ε amino of a lysine amino acid in the Glucagon-like Peptide-1 (GLP-1) agonist peptide.

### Claim 36

A compound of the formula D2:
wherein R6 is H or a nitrogen protecting group.

### Claim 37

A compound of the formula:
wherein
R3 is H or lower alkyl; and
R4 is H or a nitrogen protecting group.

### Claim 38

A compound of the formula:
wherein
R3 is H or lower alkyl; and
R5A is H or C1-C4 alkyl.
